Back to top
more

Indivior (INDV)

(Real Time Quote from BATS)

$21.86 USD

21.86
1,487,856

+0.06 (0.28%)

Updated Aug 6, 2025 11:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (83 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

All You Need to Know About Indivior (INDV) Rating Upgrade to Strong Buy

by Zacks Equity Research

Indivior (INDV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Best Momentum Stock to Buy for August 5th

by Zacks Equity Research

FFIV, INDV and NVT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 5, 2025.

Zacks Equity Research

New Strong Buy Stocks for August 5th

by Zacks Equity Research

ARMN, QUAD, NVST, INDV and BJRI have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2025.

Zacks Equity Research

Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Indivior (INDV) delivered earnings and revenue surprises of +96.15% and +22.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Indivior (INDV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Indivior (INDV) Moves 5.7% Higher: Will This Strength Last?

by Zacks Equity Research

Indivior (INDV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates

by Zacks Equity Research

IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of +50.00% and +6.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?

by Zacks Equity Research

Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?

by Zacks Equity Research

Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

RGC Resources (RGCO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Indivior PLC (INDV) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Indivior (INDV) delivered earnings and revenue surprises of 86.36% and 11.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Plus (PSTV) delivered earnings and revenue surprises of -31.37% and 6.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Indivior PLC (INDV) Q4 Earnings Meet Estimates

by Zacks Equity Research

Indivior (INDV) delivered earnings and revenue surprises of 0% and 13.98%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Indivior (INDV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Indivior (INDV) delivered earnings and revenue surprises of 38.46% and 1.57%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Rigel (RIGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Addex Stock Soars on Crucial Update From Indivior Research Deal

by Zacks Equity Research

ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.

Zacks Equity Research

Indivior PLC (INDV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Indivior (INDV) delivered earnings and revenue surprises of 10% and 4.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Indivior (INDV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

New Strong Sell Stocks for July 12th

by Zacks Equity Research

CSIQ, FMC and INDV have been added to the Zacks Rank #5 (Strong Sell) List on July 12, 2024.

Zacks Equity Research

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

by Zacks Equity Research

Indivior (INDV) slashes financial guidance for 2024, primarily to reflect adverse sales conditions of its top-selling opioid drug. It will discontinue the sales of its schizophrenia drug.

Zacks Equity Research

Indivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Indivior (INDV) delivered earnings and revenue surprises of -2.63% and 5.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Indivior (INDV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.